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In the first quarter of 2014, Cochrane collaboration, the in-
dependent, non-profit and non-governmental organization
reported that Tamiflu (with the generic name of Oseltami-
vir) is not working effectively [1]. Furthermore, it was caus-
ing side effects including vomiting, nausea, headache, renal
problems, psychiatric events, and the risk of other serious
complications such as pneumonia when used for the treat-
ment and prophylaxis of influenza. In addition, it may in-
duce serious heart rhythm problems as the drugs regulator
claims. The medicine was given to millions of people dur-
ing the swine flu pandemic. However, Roche the Swiss
drug manufacturer disagree with the overall conclusion [2]
and are awaiting the decisions from international centers
and health organizations. In the very recent article that was
published in The Lancet Respiratory Medicine’s website by
a large group of “PRIDE” consortium investigators that
was funded by F Hoffmann-La Roche, the effectiveness
of Tamiflu was revealed [3]. In this study, regardless of
its aforementioned side effects, the importance of the
neuraminidase inhibitor in the treatment of influenza A
(H1N1) and the reduction in mortality rate due to influ-
enza was discussed. Eventually, they concluded that oral
Tamiflu (oseltamivir) might reduce mortality compared
with no treatment. Regardless of this, the medicine is
still prescribed (as tablets) to patients worldwide and is
stocked until the purchased batches pass their expiry date
[1]. It is worth noting that governmental departments such
as the National Health Services (NHS) from the British
government spent millions of Sterling Pounds on stockpil-
ing the medicine in the case of a flu outcry [2]. Therefore,
being risky is considered to be better than nothing if an-
other viral pandemic suddenly becomes an epidemic, such
as in the case of the corona virus [4,5].
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article, unless otherwise stated.Consequently, to answer the question in the title and
bring up a solution to this, we insisted the urgency of
finding a replacement that is safe and efficient for treat-
ing influenza which is the number one global killer, es-
pecially in children and the elderly. Flu is a nasty disease
with new ones arising every few years. In 2006 the avian
flu viruses (H5N1 and H9N1) outbreak arose, not long
after, in 2009, the swine flu viruses (H1N1), and more re-
cently in 2013 and early 2014, the Corona virus outbreak
ensued and has already taken many lives in the Middle
East [4,5], especially in Saudi Arabia and during the Hajj
pilgrimage when millions of people are worshiping in a
huge international close gathering.
In our most recent publication [6] we discussed the
solution to viral infections by our idea of combining a
synthetic medicine called Arbidol with a natural product
called IMOD™ as a new medicine to increase their individ-
ual potency in a single dose formulation. In this paper,
IMOD™ was introduced as a powerful natural medicine
that can be effective against infectious diseases such as
AIDS due to its interferonic action which generates lym-
phocytes and consequently increases CD4 cell counts [7,8],
thereby improving life expectancy and quality of life for
afflicted patients. This would be combined with Arbidol
which is a synthetic medicine with good efficacy and no
significant side effects, as discussed in several studies
[9,10]. IMOD™ has been used within the last decade, the
latter also for more than two decades. Their pharmacokin-
etics, safety, and efficacy were subjects to many publica-
tions. These have been implemented in several human
clinical trials and influenza treatments for Arbidol. Their
toxicity was very low in animal and human studies [11,12].
Therefore, these medicines are considered to be safe for
human use and following years of prescription, no major
issues have risen so far.
In comparison, mechanistically Tamiflu and Relenza
(with generic name of zanamivir) are considered as neur-
aminidase inhibitors [1,3]. Tamiflu is administered orally
as a tablet and the latter is administered by inhalation.
The mechanisms of action for both medicines are veryd Central. This is an Open Access article distributed under the terms of the
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an enzyme that exists on the surface of the influenza virus
[2]. In comparison to this, the Arbidol-IMOD combin-
ation has a different mechanism of action. In addition to
Arbidol’s ability to react with the virus protein to disable
the virus and prevent its penetration into cells, this com-
bination is also distributed in the body quickly as an inter-
feron inducer as well as possessing antioxidant activity,
with essential elements such as selenium that boost the
immune system further [7]. Therefore, the patient’s
immune system prevents the body from becoming ill
(prophylaxis of influenza) and it also fights viral diseases
when the body needs it the most. However, the influ-
ence of IMOD™ in the treatment of influenza has not
been discussed specifically anywhere in the literature, but
the biological aspects of flavonoids in general has been the
subject of many relevant studies [13,14]. The major classes
of phytochemicals in IMOD™, including quercetin, rutin,
apigenin, catechin, etc. have been reported to possess anti-
viral activity against some types of viruses. On top of this,
they cause generation of lymphocytes and consequently
increase CD4 cell counts [7,8] thereby improving life ex-
pectancy and quality of life of viral afflicted patients which
shows the influence of IMOD™ in this preparation. In
addition, different studies have shown that IMOD™ can in-
crease interferon release from host cells significantly [8],
thus regulating Interleukin-2 levels (IL-2) [15] and conse-
quently increasing CD4 cell counts. One such interferon
is interferon gamma (IFN-γ) which is crucial for innate
and adaptive immunity. This is also the case with Arbidol,
which also shows interferonogenic activity [10]. Therefore,
the efficacy of IMOD™ in influenza was not directly the
subject of any article, but by increasing the IL-2 levels
shows it can fight infectious diseases. As a result, this pro-
vides strong evidence to indicate that IMOD™ can increase
the efficacy of Arbidol further in the treatment of pa-
tients. Consequently, the new proposed idea is expected
to produce a novel medicine that increases CD4 cell
numbers, boosts the immune system further, and thus
will be a better choice to prevent and cure viral infec-
tious diseases in general.
It must be emphasized that chemically, Arbidol itself
is a bromo-indol compound and in general, indols and
especially the bromo-substituted ones are considered to
be good sources against infectious viruses such as HIV
and hepatitis B and C [16,17].
The toxicology studies of the novel medicine was car-
ried out in mice by the investigators and showed practic-
ally zero toxicity for doses ranging from 2 g/kg to up to
4 g/Kg (unpublished data). Of course, a battery of geno-
toxicity and pharmacokinetic studies including drug inter-
action tests and related tests for immunosuppressive
patients will be explored deeply for such a novel medicine
in further studies.The Authors believe with the new hypotheses and idea
of the combination of Arbidol and IMOD™ [6], a stron-
ger agent with a new formulation as discussed can bring
a safe, effective medicine for preventing and curing
infectious diseases such as different types of influenza, if
the planned clinical trials and pharmacokinetic studies
prove promising.
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